Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...

Concern about overnight hypoglycemic events drives decision-making for patients with type 1 diabetes. For persons with type 1 diabetes (T1D) fear of the overnight hypoglycemic event drives care ...

BARCELONA, Spain, Sept. 19, 2019 /PRNewswire/ -- According to new data from the CONCLUDE head-to-head trial, Tresiba ® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a ...

* Novo Nordisk says trial demonstrated that tresiba met primary endpoint of non-inferiority compared with insulin glargine u100 for major adverse cv events * results from secondary endpoints of trial ...

Novo Nordisk will be breathing a huge sigh of relief after US regulators finally opened the door to its re-filed diabetes drugs Tresiba and Ryzodeg. Novo Nordisk will be breathing a huge sigh of ...

New studies on the effectiveness of Novo Nordisk's newest insulin have not been enough to convince Express Scripts to give it preferred status on its formulary. New studies on the effectiveness of ...

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW) approved ...

Novo Nordisk (NVO) said new data from a phase 3a trial showed that more people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with its own once-daily therapy ...

The news keeps getting better for patients with diabetes. Novo Nordisk has announced it is lowering the list prices of several insulin products by up to 75% for people living with type 1 and type 2 ...